Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics' stock price has been impacted by advancements in pipeline assets, including the NDA submission for zipalertinib and Fast Track designation for CLN-049. The company reported a robust financial position with $439.0 million in cash and investments as of December 31, 2025, projecting a cash runway into 2029. Positive analyst coverage and price target upgrades have boosted market sentiment. The company's Q4 2025 earnings surpassed analyst expectations. The stock price increased significantly over the last 12 months and year-to-date. Insider activity in March 2026 involved the Chief Scientific Officer exercising stock options and selling shares.

As a clinical-stage biopharmaceutical company without commercialized products, Cullinan Therapeutics, Inc. does not have discernible demand seasonality. Demand for its future products will be driven by clinical efficacy, regulatory approvals, and market adoption within the oncology and autoimmune disease therapeutic areas.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and autoimmune diseases. The company operates in the Biotechnology and Drug Discovery industries, identifying targets that inhibit key disease drivers or harness the immune system. Its pipeline includes zipalertinib for NSCLC, CLN-049 for AML or myelodysplastic syndrome, CLN-978 for SLE and RA, CLN-619 for solid tumors, CLN-418 for multiple solid tumors, and CLN-617 for solid tumors.

Cullinan Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States. The company focuses on developing oncology therapies for cancer patients in the United States.

Cullinan Therapeutics has maintained a generally positive brand reputation, driven by positive developments in its clinical pipeline and favorable analyst sentiment. The company has a consensus rating of "Moderate Buy" from analysts. Key events contributing to its positive reputation include advancements in pipeline assets, strong financial results, and participation in investor and healthcare conferences. There have been no explicitly reported negative events significantly impacting the company's brand reputation in the past year.

Cullinan Therapeutics, Inc. has a significant institutional ownership presence, with 157 institutional owners and shareholders holding 104.40% of the stock. Major institutional owners include Lynx1 Capital Management LP, MPM Oncology Impact Management LP, and BlackRock, Inc. The largest individual shareholder is Ansbert Gadicke, owning 26.70% of the company. Insiders collectively own 80.93% of the company, while retail investors hold 0.00%.